- $448.78m
- $446.61m
- $99.99m
Annual cashflow statement for Neuropace, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -36.1 | -47.1 | -33 | -27.1 | -21.5 |
| Depreciation | |||||
| Non-Cash Items | 10.8 | 14.7 | 15.6 | 14.4 | 14.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.368 | -4.79 | -2.48 | -5.45 | -4.01 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -24.6 | -36.9 | -19.7 | -17.9 | -11 |
| Capital Expenditures | -0.384 | -0.603 | -0.173 | -0.306 | -0.332 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -85 | 24.4 | 23.2 | 9.3 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -85.4 | 23.8 | 23 | 8.99 | -0.332 |
| Financing Cash Flow Items | -3.39 | -0.406 | -0.564 | -0.881 | -0.543 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 103 | 0.49 | 8.13 | 4.33 | 19.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -7.45 | -12.6 | 11.5 | -4.63 | 8.26 |